<p>泰瓦製藥工業有限公司（NYSE:TEVA - 獲取免費報告）在週一創下了 52 周的新高，此前 Piper Sandler 將其股票目標價從 30.00 美元上調至 40.00 美元。Piper Sandler 目前對該股票給予超配評級。泰瓦製藥的股價最高達到 30.98 美元，最後交易價為 30.9730 美元，成交量為 1205448 股。該股票此前收盤價為 30.35 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>TEVA 已成為多份研究報告的主題。高盛集團在週五的研究報告中將泰瓦製藥的目標價從 31.00 美元上調至 35.00 美元，並給予該公司 “買入” 評級。瑞銀集團在 9 月 24 日的研究報告中將泰瓦製藥的目標價從 23.00 美元上調至 26.00 美元，並給予該公司 “買入” 評級。巴克萊在 12 月 9 日的研究報告中開始覆蓋泰瓦製藥的股票，給予 “超配” 評級和 35.00 美元的目標價。摩根大通在 12 月 16 日的研究報告中將泰瓦製藥的目標價從 28.00 美元上調至 35.00 美元，並給予該公司 “超配” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對泰瓦製藥的 “賣出（d-）” 評級。三位股票研究分析師給予該股票強烈買入評級，六位給予買入評級，一位給予賣出評級。根據 MarketBeat.com，該公司目前的共識評級為 “買入”，共識目標價為 32.88 美元。</p>
<p><strong>查看我們關於 TEVA 的最新報告</strong></p>
<h2>內部活動</h2>
<ul>
<li>泰瓦製藥：為什麼這家仿製藥巨頭現在是一個明智的投資</li>
</ul>
<p>在其他泰瓦製藥的新聞中，副總裁 Richard Daniell 在 12 月 9 日的交易中出售了 115,468 股公司的股票。該股票以 28.68 美元的平均價格出售，總價值為 3,311,622.24 美元。交易完成後，該副總裁持有 48,384 股公司的股票，價值約為 1,387,653.12 美元。這一交易使其持股減少了 70.47%。該出售在向證券交易委員會的備案中披露，相關信息可以通過此鏈接訪問。此外，首席會計官 Amir Weiss 在 12 月 16 日的交易中出售了 12,300 股泰瓦製藥的股票。該股票以 30.20 美元的平均價格出售，總交易額為 371,460.00 美元。交易完成後，首席會計官持有 5,650 股公司的股票，價值為 170,630 美元。這代表其持股減少了 68.52%。該出售的 SEC 備案提供了更多信息。在過去三個月中，內部人士出售了 622,060 股公司股票，價值 17,076,965 美元。當前內部人士持有 0.55% 的股票。</p>
<h2>機構投資者對泰瓦製藥的看法</h2>
<p>一些對沖基金最近調整了對 TEVA 的持股。Advisors Asset Management Inc.在第二季度購買了泰瓦製藥的股票，價值 41,000 美元。Cromwell Holdings LLC 在第三季度將其在泰瓦製藥的持股增加了 40.3%。Cromwell Holdings LLC 現在擁有 2,191 股公司的股票，價值 44,000 美元，此前在上個季度購買了 629 股。Sound Income Strategies LLC 在第二季度將其在泰瓦製藥的持股增加了 3,715.8%。Sound Income Strategies LLC 現在擁有 2,900 股公司的股票，價值 49,000 美元，此前在上個季度購買了 2,824 股。MAI Capital Management 在第二季度將其在泰瓦製藥的持股增加了 26.8%。MAI Capital Management 現在擁有 3,293 股公司的股票，價值 55,000 美元，此前在上個季度購買了 697 股。最後，Rothschild Investment LLC 在第三季度將其在泰瓦製藥的持股增加了 97.0%。Rothschild Investment LLC 現在擁有 2,738 股公司的股票，價值 55,000 美元，此前在上個季度購買了 1,348 股。機構投資者持有該公司 54.05% 的股票。</p>
<h2>泰瓦製藥股票表現</h2>
<ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
<p>該公司的 50 日移動平均線為 24.44 美元，200 日移動平均線為 20.08 美元。公司的市值為 355.5 億美元，市盈率為 51.62，市盈增長比率為 1.81，貝塔值為 0.67。該公司的速動比率為 0.82，流動比率為 1.11，債務股本比率為 2.31。</p>
<h2>關於泰瓦製藥工業</h2>
<p>（獲取免費報告）</p>
<p>泰瓦製藥工業有限公司 NYSE: TEVA 是一家以色列跨國製藥公司，也是全球最大的仿製藥製造商之一。公司的核心業務包括仿製藥的開發、生產和營銷，以及一系列專利品牌藥物的組合。泰瓦向全球市場提供成品劑型和活性藥物成分（APIs），並在多個國家運營製造和研究設施。</p>
<p>泰瓦的產品範圍涵蓋口服固體劑型、注射劑、吸入產品及其他劑型，涉及中樞神經系統疾病、呼吸系統、腫瘤、疼痛和傳染病等治療領域。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票超過泰瓦製藥</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>“客户銀行存款面臨 6.6 萬億美元的風險”</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在梯瓦製藥嗎？</h2>
<p>在考慮梯瓦製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而梯瓦製藥並不在名單上。</p>
<p>雖然梯瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

梯瓦制藥

<p>梯瓦製藥 (NYSE:TEVA) 在皮博格·桑德勒將其目標價從 30.00 美元上調至 40.00 美元並維持增持評級後，達到了新的 52 周高點。其他分析師，包括高盛和瑞銀，也上調了他們的目標價。內部交易活動顯示公司高管進行了大量股票出售。機構投資者增加了他們的持股。該公司的市值為 355.5 億美元，市盈率為 51.62</p>

<p>Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) reached a new 52-week high on Monday after Piper Sandler raised their price target on the stock from $30.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $30.98 and last traded at $30.9730, with a volume of 1205448 shares trading hands. The stock had previously closed at $30.35.</p>
<div class="lb-trans"><p>泰瓦製藥工業有限公司（NYSE:TEVA - 獲取免費報告）在週一創下了 52 周的新高，此前 Piper Sandler 將其股票目標價從 30.00 美元上調至 40.00 美元。Piper Sandler 目前對該股票給予超配評級。泰瓦製藥的股價最高達到 30.98 美元，最後交易價為 30.9730 美元，成交量為 1205448 股。該股票此前收盤價為 30.35 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>TEVA has been the subject of a number of other research reports. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $35.00 target price on the stock. JPMorgan Chase &amp; Co. lifted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $32.88.</p>
<div class="lb-trans"><p>TEVA 已成為多份研究報告的主題。高盛集團在週五的研究報告中將泰瓦製藥的目標價從 31.00 美元上調至 35.00 美元，並給予該公司 “買入” 評級。瑞銀集團在 9 月 24 日的研究報告中將泰瓦製藥的目標價從 23.00 美元上調至 26.00 美元，並給予該公司 “買入” 評級。巴克萊在 12 月 9 日的研究報告中開始覆蓋泰瓦製藥的股票，給予 “超配” 評級和 35.00 美元的目標價。摩根大通在 12 月 16 日的研究報告中將泰瓦製藥的目標價從 28.00 美元上調至 35.00 美元，並給予該公司 “超配” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對泰瓦製藥的 “賣出（d-）” 評級。三位股票研究分析師給予該股票強烈買入評級，六位給予買入評級，一位給予賣出評級。根據 MarketBeat.com，該公司目前的共識評級為 “買入”，共識目標價為 32.88 美元。</p>
</div><p><strong>View Our Latest Report on TEVA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TEVA 的最新報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>泰瓦製藥：為什麼這家仿製藥巨頭現在是一個明智的投資</li>
</ul>
</div><p>In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares of the company's stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company's stock, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last three months. 0.55% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他泰瓦製藥的新聞中，副總裁 Richard Daniell 在 12 月 9 日的交易中出售了 115,468 股公司的股票。該股票以 28.68 美元的平均價格出售，總價值為 3,311,622.24 美元。交易完成後，該副總裁持有 48,384 股公司的股票，價值約為 1,387,653.12 美元。這一交易使其持股減少了 70.47%。該出售在向證券交易委員會的備案中披露，相關信息可以通過此鏈接訪問。此外，首席會計官 Amir Weiss 在 12 月 16 日的交易中出售了 12,300 股泰瓦製藥的股票。該股票以 30.20 美元的平均價格出售，總交易額為 371,460.00 美元。交易完成後，首席會計官持有 5,650 股公司的股票，價值為 170,630 美元。這代表其持股減少了 68.52%。該出售的 SEC 備案提供了更多信息。在過去三個月中，內部人士出售了 622,060 股公司股票，價值 17,076,965 美元。當前內部人士持有 0.55% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>機構投資者對泰瓦製藥的看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of TEVA. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth $41,000. Cromwell Holdings LLC grew its position in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter. MAI Capital Management increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company's stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Finally, Rothschild Investment LLC lifted its position in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after buying an additional 1,348 shares in the last quarter. Institutional investors own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了對 TEVA 的持股。Advisors Asset Management Inc.在第二季度購買了泰瓦製藥的股票，價值 41,000 美元。Cromwell Holdings LLC 在第三季度將其在泰瓦製藥的持股增加了 40.3%。Cromwell Holdings LLC 現在擁有 2,191 股公司的股票，價值 44,000 美元，此前在上個季度購買了 629 股。Sound Income Strategies LLC 在第二季度將其在泰瓦製藥的持股增加了 3,715.8%。Sound Income Strategies LLC 現在擁有 2,900 股公司的股票，價值 49,000 美元，此前在上個季度購買了 2,824 股。MAI Capital Management 在第二季度將其在泰瓦製藥的持股增加了 26.8%。MAI Capital Management 現在擁有 3,293 股公司的股票，價值 55,000 美元，此前在上個季度購買了 697 股。最後，Rothschild Investment LLC 在第三季度將其在泰瓦製藥的持股增加了 97.0%。Rothschild Investment LLC 現在擁有 2,738 股公司的股票，價值 55,000 美元，此前在上個季度購買了 1,348 股。機構投資者持有該公司 54.05% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Stock Performance</h2>
<div class="lb-trans"><h2>泰瓦製藥股票表現</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
</div><p>The business has a 50 day moving average of $24.44 and a 200 day moving average of $20.08. The company has a market capitalization of $35.55 billion, a P/E ratio of 51.62, a price-to-earnings-growth ratio of 1.81 and a beta of 0.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 24.44 美元，200 日移動平均線為 20.08 美元。公司的市值為 355.5 億美元，市盈率為 51.62，市盈增長比率為 1.81，貝塔值為 0.67。該公司的速動比率為 0.82，流動比率為 1.11，債務股本比率為 2.31。</p>
</div><h2>About Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>關於泰瓦製藥工業</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.</p>
<div class="lb-trans"><p>泰瓦製藥工業有限公司 NYSE: TEVA 是一家以色列跨國製藥公司，也是全球最大的仿製藥製造商之一。公司的核心業務包括仿製藥的開發、生產和營銷，以及一系列專利品牌藥物的組合。泰瓦向全球市場提供成品劑型和活性藥物成分（APIs），並在多個國家運營製造和研究設施。</p>
</div><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p>
<div class="lb-trans"><p>泰瓦的產品範圍涵蓋口服固體劑型、注射劑、吸入產品及其他劑型，涉及中樞神經系統疾病、呼吸系統、腫瘤、疼痛和傳染病等治療領域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過泰瓦製藥</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>“客户銀行存款面臨 6.6 萬億美元的風險”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在梯瓦製藥嗎？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮梯瓦製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而梯瓦製藥並不在名單上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然梯瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

梯瓦製藥（NYSE:TEVA）因分析師上調評級而創下 1 年新高